BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24943383)

  • 1. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.
    Krammer F; Jul-Larsen A; Margine I; Hirsh A; Sjursen H; Zambon M; Cox RJ
    Clin Vaccine Immunol; 2014 Aug; 21(8):1153-63. PubMed ID: 24943383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation.
    Wang Y; Lv Y; Niu X; Dong J; Feng P; Li Q; Xu W; Li J; Li C; Li J; Luo J; Li Z; Liu Y; Tan YJ; Pan W; Chen L
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32796071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent H7 immunogens offer protection from H7N9 virus challenge.
    Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
    J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
    Henry Dunand CJ; Leon PE; Huang M; Choi A; Chromikova V; Ho IY; Tan GS; Cruz J; Hirsh A; Zheng NY; Mullarkey CE; Ennis FA; Terajima M; Treanor JJ; Topham DJ; Subbarao K; Palese P; Krammer F; Wilson PC
    Cell Host Microbe; 2016 Jun; 19(6):800-13. PubMed ID: 27281570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
    Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.
    Mallett CP; Beaulieu E; Joly MH; Baras B; Lu X; Liu F; Levine MZ; Katz JM; Innis BL; Giannini SL
    Vaccine; 2015 Jul; 33(32):3784-7. PubMed ID: 26100923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
    Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
    J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans.
    Liu L; Nachbagauer R; Zhu L; Huang Y; Xie X; Jin S; Zhang A; Wan Y; Hirsh A; Tian D; Shi X; Dong Z; Yuan S; Hu Y; Krammer F; Zhang X; Xu J
    J Infect Dis; 2017 Feb; 215(4):518-528. PubMed ID: 28380622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
    Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
    Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
    Tan GS; Leon PE; Albrecht RA; Margine I; Hirsh A; Bahl J; Krammer F
    PLoS Pathog; 2016 Apr; 12(4):e1005578. PubMed ID: 27081859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
    Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
    J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
    Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
    J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
    Schmeisser F; Vasudevan A; Verma S; Wang W; Alvarado E; Weiss C; Atukorale V; Meseda C; Weir JP
    PLoS One; 2015; 10(1):e0117108. PubMed ID: 25629172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of H7N9 hemagglutinin novel protein epitopes that elicit strong antibody-dependent, cell-mediated cytotoxic activities with protection from influenza infection in mouse model.
    Zhu P; Yi X; Zhang L; Liu Y; Wang S; Gu J; Zhu X; Yu X
    Cell Immunol; 2021 Jan; 359():104255. PubMed ID: 33316647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans.
    Li M; Chen L; Wang Q; Hao M; Zhang X; Liu L; Yu X; Yang C; Xu J; Chen J; Gong R
    Antiviral Res; 2019 Oct; 170():104556. PubMed ID: 31299269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
    Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
    Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.